D-0122-2020 Class II Ongoing
FDA drug recall D-0122-2020 was initiated by Torrent Pharma Inc. on Sep 19, 2019 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million. The recall status is ongoing. Affected quantity: 39,432 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 9, 2019
- Initiation Date
- Sep 19, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 39,432 bottles
Product description
Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for: Torrent Pharma Inc., Basking Ridge, NJ 07920. NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10
Reason for recall
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.
Distribution pattern
Nationwide USA and Puerto Rico
Code information
Count, lot, expiry: [90 count] Lot 4DU3E009, exp 12/31/2020; [1000 count] Lot 4DU3D018, exp 02/28/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0122-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026